Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma (Nature Communications, (2017), 8, 1, (1738), 10.1038/s41467-017-01460-0);Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Lauss, Martin ^a   Donia, Marco ^b,c   Harbst, Katja ^a   Andersen, Rikke ^b,c   Mitra, Shamik ^a   Rosengren, Frida ^a   Salim, Maryem ^a   Vallon Christersson, Johan ^a   Törngren, Therese ^a   Kvist, Anders ^a   Ringnér, Markus ^d   Svane, Inge Marie ^b,c   Jönsson, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b Center for Cancer Immune Therapy   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NEOANTIGEN; NIVOLUMAB; PEMBROLIZUMAB; SELINEXOR; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN; BIOMARKER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENOMICS; IMMUNOASSAY; MUTATION; PREDICTION;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; CUTANEOUS MELANOMA; GENE DOSAGE; GENE EXPRESSION; HLA TYPING; HUMAN; IMMUNE-RELATED GENE; INTRAABDOMINAL METASTASIS; LYMPH NODE METASTASIS; MEDIAN SURVIVAL TIME; MELANOMA; METASTASIS; METASTATIC MELANOMA; MISSENSE MUTATION; MUCOSAL MELANOMA; MUSCLE METASTASIS; MUTATION RATE; MUTATIONAL ANALYSIS; MUTATIONAL LOAD; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SOMATIC MUTATION; SUBCUTANEOUS METASTASIS; SYSTEMIC THERAPY; T LYMPHOCYTE; TRANSCRIPTOMICS; TUMOR BIOPSY; WHOLE EXOME SEQUENCING; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MUTATION; PROCEDURES; PROGNOSIS; SECONDARY; SEQUENCE ANALYSIS; SKIN TUMOR;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MUTATION; PROGNOSIS; SEQUENCE ANALYSIS, RNA; SKIN NEOPLASMS; T-LYMPHOCYTES; WHOLE EXOME SEQUENCING;

EID: 85035025088     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-020-15531-2     Document Type: Erratum

References (58)

1. Svane, I. M. & Verdegaal, E. M. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol. Immunother. 63, 1081-1091 (2014).
2. Radvanyi, L. G. et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758-6770 (2012).
3. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
4. Besser, M. J. et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19, 4792-4800 (2013).
5. Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646-2655 (2010).
6. Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin. Cancer Res. 22, 3734-3745 (2016).
7. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
8. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
9. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
10. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
11. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
12. Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013-16018 (2005).
13. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
14. Lu, Y. C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20, 3401-3410 (2014).
15. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
16. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
17. Jonsson, G. et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 16, 3356-3367 (2010).
18. TCGA. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
19. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447-3452 (2016).
20. Bjoern, J. et al. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 5, e1100788 (2016).
21. Sade-Feldman, M. et al. Clinical significance of circulating CD33+CD11b+HLA-DR-myeloid cells in Stage-IV melanoma patients treated with ipilimumab. Clin. Cancer Res. 22, 5661-5672 (2016).
22. Ellebaek, E. et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 10, 169 (2012).
23. Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397-404e9 (2016).
24. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
25. Harbst, K. et al. Molecular profiling reveals low-and high-grade forms of primary melanoma. Clin. Cancer Res. 18, 4026-4036 (2012).
26. Cirenajwis, H. et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 6, 12297-12309 (2015).
27. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
28. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
29. Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142 (2013).
30. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
31. Nielsen, M. et al. Preclinical development of tumor infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma. Ann. Oncol. 27, 1094P (2016).
32. Stevanovic, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543-1550 (2015).
33. Westergaard, M. C. W. et al. Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer. Ann. Oncol. 27, mdw525.12 (2016).
34. Andersen, R. et al. T cell responses in the microenvironment of primary renal cell carcinoma. Ann. Oncol. 27, 1065P (2016).
35. Turcotte, S. et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J. Immunol. 191, 2217-2225 (2013).
36. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
37. Borch, T. H., Donia, M., Andersen, M. H. & Svane, I. M. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug. Discov. Today 20, 1127-1134 (2015).
38. Thor Straten, P. & Garrido, F. Targetless T cells in cancer immunotherapy. J. Immunother. Cancer 4, 23 (2016).
39. Zhao, F. et al. Melanoma lesions independently acquire T-cell resistance during metastatic latency. Cancer Res. 76, 4347-4358 (2016).
40. Sucker, A. et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin. Cancer Res. 20, 6593-6604 (2014).
41. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
42. Iglesia, M. D. et al. Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl. Cancer Inst. 108, djw144 (2016).
43. Muller, J. et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).
44. Harbst, K. et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res. 76, 4765-4774 (2016).
45. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
46. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
47. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
48. Li, J. et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics 28, 1307-1313 (2012).
49. Hupe, P., Stransky, N., Thiery, J. P., Radvanyi, F. & Barillot, E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 20, 3413-3422 (2004).
50. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
51. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
52. Hundal, J. et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 8, 11 (2016).
53. Saal, L. H. et al. The Sweden Cancerome Analysis Network-Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 7, 20 (2015).
54. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
55. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
56. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
57. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
58. Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).